Salmon R J, Fried D
Institut Curie, Paris.
Presse Med. 1998 Mar 21;27(11):509-12.
The sentinel node is defined as the first-line axillary lymphatic drainage node in breast cancer. If the sentinel node can be identified, during axillary dissection for breast cancer, resection could be limited reducing subsequent morbidity. However, before modifying the standard dissection procedure, it is important to prove that the sentinel node is representative of the metastatic status of other axillary nodes.
Between March and December 1996, 86 patients (mean age 58 years, range 32-82) underwent amputation (n = 20), tumorectomy with dissection (n = 56) or tumorectomy followed by secondary dissection (n = 10) for breast cancer. Ten ml of diluted patent blue was injected either into the peripheral portion of the tumor or the tumorectomy cavity. Node dissection was performed 10 to 20 minutes after injection. The blue sentinel node was identified prior to standard dissection.
A mean 12 nodes were removed (range 4-21). Seventy-nine sentinel nodes were identified (91%) and in 7 cases (8%) a sentinel node could not be identified. In 7 other cases the sentinel node was a false negative, i.e. non malignant despite metastases in other dissected nodes. In all the other cases, the status of the sentinel node predicted the status of the other nodes, i.e. a non-metastatic sentinel node associated with other metastatic nodes. Finally, in 7 cases, the sentinel node was the only invaded node among the nodes dissected. During the last 3 months of the study, the sentinel node was identified in 100% of the cases and was representative of the overall dissection.
Identifying the sentinel node is an alternative to standard axillary node dissection procedures. The method requires a training period and identification can be improved with radioimmunologic guidance. Patient selection within the framework of a rigorous multidisciplinary protocol is indispensable. A nationwide study is currently being conducted to validate these preliminary results.
前哨淋巴结被定义为乳腺癌腋窝淋巴引流的第一站淋巴结。如果能够识别前哨淋巴结,在乳腺癌腋窝清扫术中,切除范围可以受限,从而降低术后发病率。然而,在改变标准清扫程序之前,重要的是要证明前哨淋巴结能够代表其他腋窝淋巴结的转移状态。
1996年3月至12月期间,86例患者(平均年龄58岁,范围32 - 82岁)因乳腺癌接受了截肢手术(n = 20)、肿瘤切除加清扫术(n = 56)或肿瘤切除术后二次清扫术(n = 10)。将10毫升稀释的专利蓝注射到肿瘤周边或肿瘤切除腔内。注射后10至20分钟进行淋巴结清扫。在标准清扫之前识别蓝色前哨淋巴结。
平均切除12个淋巴结(范围4 - 21个)。共识别出79个前哨淋巴结(91%),7例(8%)未识别出前哨淋巴结。另外7例中前哨淋巴结为假阴性,即尽管其他清扫出的淋巴结有转移,但该前哨淋巴结无恶性病变。在所有其他病例中,前哨淋巴结的状态可预测其他淋巴结的状态,即非转移性前哨淋巴结与其他转移性淋巴结相关。最后,在7例中,前哨淋巴结是清扫出的淋巴结中唯一受侵的淋巴结。在研究的最后3个月,100%的病例识别出了前哨淋巴结,且其能代表整体清扫情况。
识别前哨淋巴结是标准腋窝淋巴结清扫程序的一种替代方法。该方法需要一个培训阶段,并且通过放射免疫引导可提高识别率。在严格的多学科方案框架内进行患者选择是必不可少的。目前正在进行一项全国性研究以验证这些初步结果。